Many clinical trials have demonstrated that CD19 chimeric antigen receptor T cell (CAR-T) therapy is a promising treatment for patients with relapsed or refractory (R/R) hematological malignancies (1–3). This evidence concerns the gene CD19 and hematologic disorder.